493.6500 15.95 (3.34%)
NSE Mar 25, 2026 15:31 PM
Volume: 127.4K
 

493.65
3.34%
ICICI Securities Limited
We recently hosted Akums’ management for a roadshow. Akums has been able to maintain its CDMO and overall EBITDA margin at 15.5%/12.0% despite its sub-par revenue growth in 9MFY25. Further efforts towards curbing losses in API division and new export order (starting CY27) could drive operating leverage and boost margins in coming years.
Akums Drugs & Pharma.. has an average target of 680.00 from 1 broker.
More from Akums Drugs & Pharmaceuticals Ltd.
Recommended